Related Experiment Video
Updated: Nov 21, 2025
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Xuan Fei Bai Du Fang for treating coronavirus disease 2019: A protocol for systematic review and meta-analysis
Yuying Cui1,2, Jinming Yao2,3, Guoliang Shao4
1Master of Clinical Integration in Traditional Chinese and Western Medicine, College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Ji-nan.
Insights
This review evaluates Xuan Fei Bai Du Fang for COVID-19 treatment. It synthesizes evidence on efficacy and safety, aiming to inform clinical practice for this respiratory disease.
Area of Science:
- Integrative Medicine
- Infectious Diseases
- Clinical Pharmacology
Background:
- Coronavirus disease 2019 (COVID-19) presents a significant global health challenge with high fatality rates.
- Established Chinese medicine, including "3 prescriptions and 3 drugs," offers potential therapeutic avenues.
- Xuan Fei Bai Du Fang (QFBDF) is a key component of these traditional treatments, demonstrating promising clinical effects.
Purpose of the Study:
- To systematically review and evaluate the efficacy and safety of Xuan Fei Bai Du Fang (QFBDF) in treating COVID-19.
- To provide robust evidence for the clinical application of QFBDF in managing COVID-19 patients.
Main Methods:
- Comprehensive literature search across PubMed, EMBASE, Cochrane Library, CNKI, and Wanfang databases for randomized controlled trials (RCTs).
- Rigorous screening and data extraction by two independent reviewers, with risk of bias assessment using the GRADE framework.
- Meta-analysis of pooled data using RevMan 5.3 to evaluate primary and secondary outcomes, assessing heterogeneity with Q-test and I2 statistic.
Main Results:
- The study focuses on outcomes such as the time to negative nucleic acid tests and cure rates.
- Results will be synthesized to determine the effectiveness and safety profile of QFBDF.
Conclusions:
- This systematic review aims to offer new evidence regarding the effectiveness and safety of Xuan Fei Bai Du Fang for COVID-19 treatment.
- Findings will contribute to the evidence base for traditional Chinese medicine in managing viral respiratory infections.
Background:
Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease with a high fatality rate. Up to now, there are an estimated 26 million confirmed cases and 865,000 deaths around the world. But no effective way can control this disease. As the country that first discovered and treated the COVID-19, China has formed relatively mature prevention and treatment methods such as "3 prescriptions and 3 drugs." Xuan Fei Bai Du Fang, as a member of "3 prescriptions and 3 drugs," has very good clinical effects.
Methods:
The PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases were searched for randomized controlled studies published to date. This study only screens clinical randomized controlled trials on QFBDF for COVID-19 to evaluate its efficacy and safety.Import all literatures that meet the requirements into Endnote X9 software. The information was finally cross-checked by 2 reviewers. Papers selected for review were assessed for risk of bias according to the criteria. Quality assessment on design of study, risk of bias, indirectness and imprecision were assessed using the GRADE framework. Where sufficient studies were available, publication bias was assessed visually using funnel plots. Relative risks for primary and secondary outcomes were calculated on an intent-to-treat basis and pooled using random effects meta-analysis. the continuous is expressed by mean difference or standard mean difference, eventually the data is synthesized using a fixed effect model or a random effect model depending on whether or not heterogeneity exists. The heterogeneity of studies will be evaluated by Q-test and I2 statistic with RevMan5.3.
Results:
The time from a positive diagnosis to a negative result of 2 consecutive nucleic acid tests (not on the same day), cure rate. The results of our research will be published in a peer-reviewed journal.
Conclusion:
The purpose of this systematic review is to provide new evidence for the effectiveness and safety of Xuan Fei Bai Du Fang in the treatment of COVID-19.
Prospero Registration Number:
CRD42020213950.
